InnoUp Farma
Clinical-stage Spanish biotechnology company developing a patented nanoparticle encapsulation platform based on biocompatible, bioadhesive nanoparticles. The platform is applied to oral and mucosal delivery to enable sustained release, improve oral bioavailability of poorly absorbed drugs, and act as an adjuvant for mucosal vaccines and immunotherapies. The company reports preclinical safety and PK work and has programs at clinical stage, plus experience in scaling the nanoparticle process to industrial production.
Industries
Nr. of Employees
small (1-50)
InnoUp Farma
Patents
Nanoparticles for encapsulating compounds, the preparation and uses thereof
US-10933025-B2
View DetailsNanoparticles comprising a cyclodextrin and a biologically active molecule and uses thereof
US-9522197-B2
View DetailsImmune response stimulating composition comprising nanoparticles based on a methyl vinyl ether-maleic acid copolymer
US-8895067-B2
View Details
Nanoparticles for encapsulating compounds, the preparation and uses thereof
US-10933025-B2
View DetailsNanoparticles comprising a cyclodextrin and a biologically active molecule and uses thereof
US-9522197-B2
View DetailsImmune response stimulating composition comprising nanoparticles based on a methyl vinyl ether-maleic acid copolymer
US-8895067-B2
View DetailsProducts
Oral nanoparticle formulation of paclitaxel (clinical-stage)
Nanoparticle encapsulation of paclitaxel formulated for oral administration to increase bioavailability and reduce systemic toxicity; advanced to Phase I clinical development.
Oral nanoparticle-based peanut allergy vaccine (clinical-stage)
Nanoparticle formulation encapsulating peanut allergen delivered orally to induce immune responses with an improved safety profile; clinical study in allergic patients authorized and being conducted.
Oral nanoparticle vaccine candidate with inactivated SARS-CoV-2 (preclinical)
Nanoparticle formulation containing inactivated SARS-CoV-2 intended as an oral vaccine candidate; preclinical studies ongoing to evaluate immunogenicity.
INP12
Nanoparticles with encapsulated paclitaxel designed to increase oral bioavailability with low toxicity and high efficacy as an alternative to intravenous paclitaxel.
INP30
Nanoparticles with encapsulated inactivated SARS-CoV2 for developing mucosal nanoparticle vaccine products and oral vaccines based on other viruses and bacteria.
Vacuna oral para alergia al cacahuete
Primera vacuna oral basada en nanotecnología para el tratamiento de la alergia al cacahuete, evaluada en ensayos clínicos.
Oral nanoparticle formulation of paclitaxel (clinical-stage)
Nanoparticle encapsulation of paclitaxel formulated for oral administration to increase bioavailability and reduce systemic toxicity; advanced to Phase I clinical development.
Oral nanoparticle-based peanut allergy vaccine (clinical-stage)
Nanoparticle formulation encapsulating peanut allergen delivered orally to induce immune responses with an improved safety profile; clinical study in allergic patients authorized and being conducted.
Oral nanoparticle vaccine candidate with inactivated SARS-CoV-2 (preclinical)
Nanoparticle formulation containing inactivated SARS-CoV-2 intended as an oral vaccine candidate; preclinical studies ongoing to evaluate immunogenicity.
INP12
Nanoparticles with encapsulated paclitaxel designed to increase oral bioavailability with low toxicity and high efficacy as an alternative to intravenous paclitaxel.
INP30
Nanoparticles with encapsulated inactivated SARS-CoV2 for developing mucosal nanoparticle vaccine products and oral vaccines based on other viruses and bacteria.
Vacuna oral para alergia al cacahuete
Primera vacuna oral basada en nanotecnología para el tratamiento de la alergia al cacahuete, evaluada en ensayos clínicos.
Services
Partnerships and collaboration for joint development, translational research and participation in grant-funded projects; contact for collaboration and investment inquiries via company contact channels.
Partnerships and collaboration for joint development, translational research and participation in grant-funded projects; contact for collaboration and investment inquiries via company contact channels.
Expertise Areas
- Nanoparticle drug delivery
- Oral drug formulation and bioavailability enhancement
- Mucosal vaccine and immunotherapy development
- Preclinical development and animal models
Key Technologies
- Bioadhesive nanoparticle encapsulation
- Controlled-release formulations
- Oral and mucosal delivery platforms
- Nanoparticle-based vaccine adjuvants
News & Updates
Collaborative participation in a project to develop thermostable mRNA-based vaccines against SARS-CoV-2 (Delta) funded through Next Generation EU and managed by CDTI.
Recipient of grants and public funding including awards/cofunding from regional government, Ministry of Science and Innovation, CDTI and European funds for clinical and preclinical projects.
Collaborative participation in a project to develop thermostable mRNA-based vaccines against SARS-CoV-2 (Delta) funded through Next Generation EU and managed by CDTI.
Recipient of grants and public funding including awards/cofunding from regional government, Ministry of Science and Innovation, CDTI and European funds for clinical and preclinical projects.